**Supplementary Table 1. Clinical information of the CLL patients whose samples were used in the study with the Axl inhibitor TP-0903**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CLL Patients** | **Rai Stage** | **FISH** | | **IGHV Mutational Status** | **LD50 doses of TP-0903 (M)** |
| **Low-Risk** | **High-Risk** |
| P1 | 0 | 13q- |  | M | 0.17 |
| P2 | II | Tri-12 |  | Non-functional IgVH rearrangement | 0.09 |
| P3 | IV | 13q- |  | UM | 0.09 |
| P4 | II | 13q- |  | M | 0.17 |
| P5 | IV | N/A |  | M | 0.17 |
| P6 | I | 13q- |  | M | 0.15 |
| P7 | 0 | Normal |  | M | 0.14 |
| P8 | II | N/A |  | UM | 0.14 |
| P9 | III | 13q- |  | M | 0.12 |
| P10 | I | Normal |  | UM | 0.12 |
| P11 | II | 13q- |  | M | 0.14 |
| P12 | 0 | 13q- |  | N/A | 0.11 |
| P13 | 0 | 13q- |  | N/A | 0.09 |
| P14 | III | 13q-/Tri12 |  | M/UM | 0.15 |
| P15 | I | Tri-12 |  | UM | 0.15 |
| P16 | IV | 13q- |  | UM | 0.25 |
| P17 | II | 13q- |  | M | 0.15 |
| P18 | I | 13q- |  | M | 0.14 |
| P19 | II | 13q- |  | M | 0.19 |
| P20 | II | 13q- |  | UM | 0.16 |
| P21 | 0 |  | 17p13.1 | UM | 0.12 |
| P22 | 0 |  | 17p13.1 | M | 0.17 |
| P23 | II |  | 17p13.1 | M | 0.13 |
| P24 | 0 |  | 17p13.1 | M | 0.20 |
| P25 | 0 |  | 17p13.1 | M/UM | 0.16 |
| P26 | II |  | 17p13.1 | UM | 0.09 |
| P27 | 0 |  | 17p13.1 | M | 0.15 |
| P28 | I |  | 17p13.1 | M | 0.16 |
| P29 | I |  | 11q22.3 | M | 0.13 |
| P30 | III |  | 11q22.3 | UM | 0.16 |
| P31 | 0 |  | 11q22.3 | UM | 0.15 |
| P32 | IV |  | 11q22.3 | M | 0.21 |
| P33 | II |  | 11q22.3 | UM | 0.14 |
| P34 | I |  | 11q22.3 | UM | 0.22 |
| P35 | I |  | 11q22.3 | UM | 0.13 |
| P36 | I |  | 11q22.3 | M | 0.19 |
| P37 | 0 |  | 11q22.3 | M | 0.12 |
| P38 | 0 |  | 11q22.3 | UM | 0.17 |